Results 51 to 60 of about 999,769 (295)

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis

Frontiers in Pharmacology, 2022
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by an abnormal reepithelialisation, an excessive tissue remodelling and a progressive fibrosis within the alveolar wall that are not due to infection or cancer ...
C. Estornut, J. Milara, María Amparo Bayarri, N. Belhadj, J. Cortijo   +4 more
semanticscholar   +1 more source

Bimodal fibrosis in a novel mouse model of bleomycin-induced usual interstitial pneumonia

Life Science Alliance, 2022
A novel mouse model of induced-usual interstitial pneumonia shows bimodal fibrosis with honeycombing, similar to chronic lung disease seen with idiopathic pulmonary fibrosis.
Yoko Miura, Maggie Lam, Jane E Bourke, Satoshi Kanazawa   +3 more
doaj   +1 more source

Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

British medical journal, 2022
Similarly to idiopathic pulmonary fibrosis (IPF), other interstitial lung diseases can develop progressive pulmonary fibrosis (PPF) characterized by declining lung function, a poor response to immunomodulatory therapies, and early mortality.
Gabrielle Y. Liu, G. R. Scott Budinger, Jane E. Dematte   +2 more
semanticscholar   +1 more source

Cell Therapy in Idiopathic Pulmonary Fibrosis [PDF]

, 2018
Idiopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options. In recent decades, cell-based therapies using stem cells or lung progenitor cells to regenerate lung tissue have experienced rapid growth in both ...
Anna Serrano-Mollar, Serrano-Mollar, Anna   +1 more
core   +1 more source

De Novo Discovery of Nonstandard Thioisoindole‐Bridged Bicyclic Peptides Targeting Traf2‐ and NCK‐Interacting Kinase

Angewandte Chemie, EarlyView.
An optimized strategy for the ribosomal synthesis of thioisoindole‐bridged bicyclic (TiB) peptides is incorporated into the RaPID platform, enabling high‐throughput discovery from topologically defined TiB libraries. Proof‐of‐concept selection against TNIK identifies nanomolar‐affinity ligands with inhibitory activity, while x‐ray crystallography ...
Yue Zhang, Alexander A. Vinogradov, Keisuke Hamada, Yin Sun, Toru Sengoku, Hiroaki Suga   +5 more
wiley   +2 more sources

Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis

Revista Portuguesa de Pneumologia (English Edition), 2016
Idiopathic pulmonary fibrosis is a rare interstitial lung disease included in the Idiopathic Interstitial Pneumonias group. Although several potential risk factors have been described, it is a progressive fibrosing disease of unknown cause affecting ...
C. Robalo Cordeiro, P. Campos, L. Carvalho, S. Campainha, S. Clemente, L. Figueiredo, J.M. Jesus, A. Marques, C. Souto-Moura, R. Pinto Basto, A. Ribeiro, M. Serrado, A. Morais   +12 more
doaj   +1 more source

Immune dysregulation as a driver of idiopathic pulmonary fibrosis.

Journal of Clinical Investigation, 2021
Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide, reducing their quality of life and leading to death from respiratory failure within years of diagnosis.
K. Shenderov, S. Collins, J. Powell, M. Horton   +3 more
semanticscholar   +1 more source

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.

New England Journal of Medicine
BACKGROUND Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects.
L. Richeldi, Azuma Arata, V. Cottin, Michael Kreuter, Toby M. Maher, F. Martinez, J. Oldham, Claudia Valenzuela, E. Clerisme-Beaty, M. Gordat, D. Wachtlin, Yi Liu, C. Schlecker, S. Stowasser, D. Zoz, M. Wijsenbeek   +15 more
semanticscholar   +1 more source

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

EBioMedicine, 2019
Background Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease.
J. Justice, A. Nambiar, T. Tchkonia, N. LeBrasseur, R. Pascual, S. Hashmi, L. Prata, M. Masternak, S. Kritchevsky, N. Musi, J. Kirkland   +10 more
semanticscholar   +1 more source

TGF-β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)

International Journal of Molecular Medicine, 2021
Idiopathic pulmonary fibrosis (IPF) is a worldwide disease characterized by the chronic and irreversible decline of lung function. Currently, there is no drug to successfully treat the disease except for lung transplantation.
Zhimin Ye, Yongbin Hu
semanticscholar   +1 more source